Dextran sulfate sodium-induced colitis-associated neoplasia: A promising model for the development of chemopreventive interventions

Acta Pharmacologica Sinica

Volumn 28, Issue 9, 2007, Pages 1450-1459

  Clapper, Margie Lee ^a   Cooper, Harry Stanley ^a   Chang, Wen Chi Lee ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemoprevention; Colorectal colitis; Dextran sulfate sodium; Mouse models

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 2 AMINO 3 METHYLIMIDAZO[4,5 F]QUINOLINE; ACETYLCYSTEINE; AZOXYMETHANE; DEXTRAN SULFATE; FLUINDOSTATIN; IRON; MESALAZINE; NIMESULIDE; PHYTIC ACID; PRENYLOXYCOUMARIN DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLITIS; COLON CANCER; COLON POLYPOSIS; COLORECTAL DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DYSPLASIA; HISTOPATHOLOGY; NONHUMAN; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; COLITIS; COLONIC NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL;

EID: 34548379030     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00695.x     Document Type: Review

References (66)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001 48 : 526 35.
2. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000 321 : 886 9.
3. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Sem Diagn Pathol 1996 13 : 339 57.
4. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990 323 : 1228 33.
5. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006 130 : 1030 8.
6. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002 359 : 331 40.
7. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcer-ative colitis. Gastroenterology 2003 124 : 880 8.
8. Kern SE, Redston M, Seymour AB, Caldas C, Powell SM, Kornacki S, et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology 1994 107 : 420 8.
9. Aust DE, Terdiman J P, Willenbucher R F, Chang CG, Molinaro-Clark A, Baretton GB, et al. The APC/β-catenin pathway in ulcerative colitis-related colorectal carcinomas. A mutational analysis. Cancer 2002 94 : 1421 7.
10. 53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000 60 : 3333 7.
11. Brentnall TA, Crispin DA, Bronner M P, Cherian S P, Hueffed M, Rabinovitch PS, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996 56 : 1237 40.
12. Chang CL, Marra G, Chauhan DP, Ha HT, Chang DK, Ricciardiello L, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002 283 : C148 54.
13. Fogt F, Vortmeyer AO, Goldman H, Giordano TJ, Merino MJ, Zhuang Z. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 1998 29 : 131 6.
14. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001 61 : 2676 83.
15. Wong NACS, Harrison DJ. Colorectal neoplasia in ulcerative colitis - recent advances. Histopathology 2001 39 : 221 34.
16. Ohkusa T. Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and change in intestinal microflora. Jpn J Gastroenterol 1985 82 : 1327 36.
17. Okayasu I, Hatekayama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990 98 : 694 702.
18. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993 69 : 238 49.
19. Min/+ mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 2006 118 : 25 34.
20. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000 21 : 757 68.
21. Nosho K, Yamamoto H, Adachi Y, Endo T, Hinoda Y, Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer 2005 92 : 1193 200.
22. Cooper HS, Everley L, Chang W-C, Pfeiffer G, Lee B, Murthy S, et al. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 2001 121 : 1407 16.
23. Coudry RA, Cooper HS, Gary M, Lubet RA, Chang WCL, Clapper ML. Correlation of inhibition of colitis-associated dysplasia by celecoxib with degree of inflammation in the mouse model of DSS-induced colitis. Proc Am Assoc Cancer Res 2004 45 : 548.
24. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003 94 : 965 73.
25. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006 27 : 162 9.
26. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000 21 : 1117 20.
27. Tanaka T, Suzuki R, Kohno H, Sugie S, Takahashi M, Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess β-catenin gene mutations and increases immunoreactivity for β-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005 26 : 229 38.
28. Aust DE, Terdiman JP, Willenbucher RF, Chew K, Ferrell L, Florendo C, et al. Altered distribution of β-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol 2001 14 : 29 39.
29. Souza RF, Yin J, Smolinski KN, Zou TT, Wang S, Shi YQ, et al. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res 1997 57 : 2350 3.
30. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 2000 21 : 387 95.
31. Nagao M. A new approach to risk estimation of food-borne carcinogens - heterocyclic amines - based on molecular information. Mutat Res 1999 431 : 3 12.
32. Sugimura T. Overview of carcinogenic heterocyclic amines. Mutat Res 1997 376 : 211 9.
33. Nishikawa A, Imazawa T, Kuroiwa Y, Kitamura Y, Kanki K, Ishii Y, et al. Induction of colon tumors in C57BL/6J mice fed MeIQx, IQ, or PhIP followed by dextran sulfate sodium treatment. Toxicol Sci 2005 84 : 243 8.
34. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 2002 132 : 3146 50.
35. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 2002 47 : 1266 78.
36. +/Min-FCCC) mice with significantly increased numbers of colorectal adenomas. Mol Carcinog 2005 44 : 31 41.
37. Burmer GC, Crispin DA, Kolli VR, Haggitt RC, Kulander BG, Rubin CE, et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991 3 : 167 72.
38. Chang WC, Coudry RA, Clapper ML, Zhang X, Williams KL, Spittle CS, et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis 2007 June 8 [Epub ahead of print].
39. Fujii S, Fujimori T, Kawamata H, Takeda J, Kitajima K, Omotehara F, et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 2004 53 : 710 6.
40. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998 19 : 711 21.
41. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol 2001 281 : G626 G34.
42. Seril DN, Liao J, Yang GY. Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol Carcinog 2007 46 : 341 53.
43. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000 60 : 4864 8.
44. Cawkwell L, Sutherland F, Murgatroyd H, Jarvis P, Gray S, Cross D, et al. Defective hMSH2/hMLH1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers. Gut 2000 46 : 367 9.
45. Kohonen-Corish MR, Daniel JJ, te Riele H, Buffinton GD, Dahlstrom JE. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res 2002 62 : 2092 7.
46. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87 : 803 9.
47. Steinbach G, Lynch P, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000 342 : 1946 52.
48. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002 97 : 910 4.
49. Kapicioglu S, Baki AH, Sari M, Ozdemir F, Kavgaci H. Does nimesulide induce gastric mucosal damage? "A double-blind randomized placebo-controlled trial". Hepatogastroenterology 2000 47 : 1183 5.
50. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005 5 : 46.
51. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003 63 : 6090 5.
52. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci USA 2002 99 : 13771 6.
53. Min/+ mice. Nat Med 1998 4 : 1053 7.
54. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al. Activators of the nuclear receptor PPAR? enhance colon polyp formation. Nat Med 1998 4 : 1058 61.
55. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001 61 : 2424 8.
56. Gary MA, Coudry RA, Cooper HS, Litwin S, Concha AC, Lubet RA, et al. 5-Aminosalicylic acid inhibits colitis-associated dysplasia in the mouse model of AOM/DSS-induced colitis. Proc Am Assoc Cancer Res Third Annual International Conference on Frontiers in Cancer Prevention Research 2004 45 : A81.
57. Grimm GR, Dirisina R, Lee G, Tang Y, Manjali J, Hanson NB, et al. 5-ASA suppressed induction of dysplasia on the AOM/DSS model: Correlation with inhibition of Wnt/beta-catenin transcriptional activity. Gastroenterology 2005 128 (Suppl 2 A200.
58. Seril DN, Liao J, Ho KL, Yang CS, Yang GY. Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 2002 23 : 993 1001.
59. Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. Physiol Rev 1999 79 : 1373 430.
60. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hyper-cholesterolemia and atherosclerosis. Circulation 1987 76 : 504 7.
61. Suzuki S, Tajima T, Sassa S, Kudo H, Okayasu I, Sakamoto S. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res 2006 26 : 4223 8.
62. Raboy V. Myo-Inositol-1,2,3,4,5,6-hexakisphosphate. Phytochemistry 2003 64 : 1033 43.
63. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: a systematic review. Complement Ther Med 2002 10 : 229 34.
64. Liao J, Seril DN, Yang AL, Lu GG, Yang GY. Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis 2007 28 : 446 54.
65. Tanaka T, Kawabata K, Kakumoto M, Makita H, Hara A, Mori H, et al. Citrus auraptene inhibits chemically induced colonic aberrant crypt foci in male F344 rats. Carcinogenesis 1997 18 : 2155 61.
66. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, et al. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int J Cancer 2006 118 : 2936 42.